Cannabis News

Brazil CBD and Cannabis Regulation Report 2022 –

Columbia Care is among the first group of 7 operators to receive approval to begin sales for adult use

NEW YORK–(BUSINESS WIRE)–Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest cultivators, manufacturers and suppliers of cannabis products and Most Experienced in the United States, announced that it will begin adult sales today at its two New Jersey dispensaries, both now under the Cannabist brand, in Deptford and Vineland. Cannabist Deptford is located at 1692 Clements Bridge Road in Deptford; Cannabiste Vineland is located at 1062 N. Delsea Dr.

“This is a momentous moment for Garden State voters who have been looking forward to adult-use sales, giving new meaning to the phrase ‘good things come to those who wait,'” said Nicholas Vita, CEO of ColumbiaCare. “We are grateful to the New Jersey Cannabis Regulatory Commission for giving us the green light to begin sales of our high-quality cannabis products to recreational customers on day one for New Jersey, and we are grateful to the local authorities and communities for their continued support. . New Jersey is the first in the next wave of East Coast states to launch adult use, and we’re excited to grow and evolve alongside new social equity entrepreneurs who will help make this local industry a success.

The Deptford and Vineland locations will open to adult sales with limited hours, which will expand as demand and market dynamics change. Each location will offer physician-only hours, as well as physician-only parking spaces, pick-up lines and dedicated phone lines to ensure patient access is not impacted by the start of adult sales.

The adult menu will launch with some of the company’s most popular flower varieties, available in 3.5g and 7.5g packs, as well as two vape options. New products and form factors, including concentrated oils, resin, tinctures, lozenges and soft chews, will also be added to the adult menu, after meeting third-party testing requirements. ‘State.

In addition to its two existing dispensaries in Deptford and Vineland, Columbia Care is licensed to operate a third retail outlet, which is under development. The company currently operates a 50,000 square foot cultivation and production facility in Vineland, with a second Vineland facility currently in development that will provide an additional 270,000 square feet of canopy, manufacturing and distribution space, pending release. regulatory approval.

Columbia Care will donate a portion of the proceeds from the company’s first adult sales to the Shiloh Baptist Church in Vineland to support its reintegration program.

For hours, menu and dispensary information, visit For medical information for patients, visit

About Columbia Care

Columbia Care is one of the largest and most experienced cultivators, manufacturers and suppliers of cannabis products and related services, with licenses in 18 US jurisdictions and the EU. Columbia Care operates 131 facilities, including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the first multi-state providers of medical cannabis in the United States and now offers industry-leading products and services to the medical and adult markets. In 2021, the company launched Cannabist, its new retail brand, creating a nationwide network of dispensaries that relies on proprietary technology platforms. The company offers products spanning flowers, edibles, oils, and tablets, and manufactures popular brands such as Seed & Strain, Triple Seven, gLeaf, Classix, Press, Amber, and Platinum Label CBD. For more information about Columbia Care, please visit

Caution Regarding Forward-Looking Statements

This press release contains certain statements that constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Forward-looking statements or information contained in this release include, but are not limited to, statements or information regarding the company’s ability to execute retail, wholesale, brand and product initiatives in New Jersey. . Such forward-looking statements or information, which, although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. These risks, uncertainties and other factors include, among others, favorable operating and economic conditions; obtain and maintain all required licenses and permits; favorable production levels and sustained costs of the Company’s operations; and the level of demand for cannabis products, including the Company’s products sold by third parties. In addition, securityholders should consider the risk factors described under “Risk Factors” in Columbia Care’s Form 10-K dated March 31, 2022, filed with the United States Securities and Exchange Commission and with competent Canadian securities authorities on SEDAR at and as otherwise described from time to time in the Company’s filings with Canadian and US securities regulators.


Lee Ann Evans

Investor Relations

Lindsay Wilson



This Publish was originally published on This site

#Brazil #CBD #Cannabis #Regulation #Report #ResearchAndMarketscom

Related Posts

Leave a Reply